GlassScriptPhysician profile
John S Videen
NPI 1043318199
$29,067.08
in general payments reported to CMS, 2019-2025
39 companies · $1,294 in 2025
The $1,294 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $548 · 2021: $1,338 · 2022: $1,562 · 2023: $11K · 2024: $1,708 · 2025: $1,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,330 · Food and Beverage: $5,135 · Travel and Lodging: $952 · Education: $32.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,330.00 |
| Food and Beverage | $5,134.64 |
| Travel and Lodging | $952.38 |
| Education | $32.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $8,256.50 | 2021-2023 | |
| Fresenius USA Marketing, INC. | $5,155.24 | 2019-2025 | Velphoro, Velphoro |
| Calliditas Therapeutics US INC. | $2,511.74 | 2022-2024 | Tarpeyo |
| Grifols Biologicals LLC | $2,489.89 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $1,809.09 | 2019-2025 | Farxiga |
| Baxter Healthcare | $1,700.00 | 2019 | |
| Amgen INC. | $1,245.50 | 2019-2025 | Krystexxa, Tavneos |
| Horizon Therapeutics Plc | $619.24 | 2021-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $463.19 | 2021-2024 | Lupkynis |
| Nxstage Medical, INC. | $447.94 | 2022-2025 | Nxstage System One |
| Alexion Pharmaceuticals, INC. | $442.17 | 2019-2024 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $430.84 | 2020-2024 | Terlivaz |
| Vifor Pharma, INC. | $427.14 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $343.44 | 2019-2025 | Jynarque |
| Dexcom, INC. | $259.09 | 2021-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Videen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.